Aposcience

Aposcience AG is a private, clinical-stage biotech pioneering a novel regenerative medicine platform based on the therapeutic secretome of white blood cells. The company is advancing its lead candidate, APOSEC, through clinical trials for severe conditions like diabetic foot ulcers and myocardial infarction, with recent milestones including the completion of patient treatment in its MARSYAS II study. Operating as a pre-revenue entity, Aposcience targets significant unmet needs in wound care and ischemic diseases, positioning its cell-free, protein-based therapy as a potential transformative alternative to complex cell therapies. Its approach leverages the paracrine signaling factors of immune cells to promote healing and modulate inflammation.

Proprietary platform based on the therapeutic secretome (proteins, growth factors, vesicles) of stimulated peripheral blood mononuclear cells (PBMCs) for regenerative and immunomodulatory applications.

Aposcience competes in the crowded regenerative medicine space against large pharma and biotechs developing cell therapies, growth factors, and other biologics for wounds and cardiovascular repair. Its key competitive edge is the acellular, paracrine-based approach, but it must demonstrate superior efficacy or safety to gain market share.